These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19634160)

  • 1. Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines.
    Drozdov I; Kidd M; Gustafsson BI; Svejda B; Joseph R; Pfragner R; Modlin IM
    Cancer; 2009 Nov; 115(21):4934-45. PubMed ID: 19634160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.
    Kidd M; Drozdov I; Joseph R; Pfragner R; Culler M; Modlin I
    Cancer; 2008 Aug; 113(4):690-700. PubMed ID: 18618499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment.
    Svejda B; Kidd M; Giovinazzo F; Eltawil K; Gustafsson BI; Pfragner R; Modlin IM
    Cancer; 2010 Jun; 116(12):2902-12. PubMed ID: 20564397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.
    Kidd M; Schally AV; Pfragner R; Malfertheiner MV; Modlin IM
    Cancer; 2008 Mar; 112(6):1404-14. PubMed ID: 18224665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRJ-I and BON cell lines: defining an appropriate enterochromaffin cell neuroendocrine tumor model.
    Siddique ZL; Drozdov I; Floch J; Gustafsson BI; Stunes K; Pfragner R; Kidd M; Modlin IM
    Neuroendocrinology; 2009; 89(4):458-70. PubMed ID: 19295186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin and the 5-HT7 receptor: the link between hepatocytes, IGF-1 and small intestinal neuroendocrine tumors.
    Svejda B; Kidd M; Timberlake A; Harry K; Kazberouk A; Schimmack S; Lawrence B; Pfragner R; Modlin IM
    Cancer Sci; 2013 Jul; 104(7):844-55. PubMed ID: 23578138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
    Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
    Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines.
    Dizeyi N; Hedlund P; Bjartell A; Tinzl M; Austild-Taskén K; Abrahamsson PA
    Urol Oncol; 2011; 29(4):436-45. PubMed ID: 19926313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of 5-HT1, 5-HT2, and 5-HT3 receptors in the mediation of the prolactin response to serotonin and 5-hydroxytryptophan.
    Jørgensen H; Knigge U; Warberg J
    Neuroendocrinology; 1992 Mar; 55(3):336-43. PubMed ID: 1386914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.
    Gilbert JA; Adhikari LJ; Lloyd RV; Rubin J; Haluska P; Carboni JM; Gottardis MM; Ames MM
    Endocr Relat Cancer; 2010 Sep; 17(3):623-36. PubMed ID: 20385747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tryptophan hydroxylase 1 and 5-HT
    Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
    Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coexpression of 5-HT2A and 5-HT4 receptors coupled to distinct signaling pathways in human intestinal muscle cells.
    Kuemmerle JF; Murthy KS; Grider JR; Martin DC; Makhlouf GM
    Gastroenterology; 1995 Dec; 109(6):1791-800. PubMed ID: 7498643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiserotonergic properties of terguride in blood vessels, platelets, and valvular interstitial cells.
    Kekewska A; Görnemann T; Jantschak F; Glusa E; Pertz HH
    J Pharmacol Exp Ther; 2012 Feb; 340(2):369-76. PubMed ID: 22049464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexistence of contractile and relaxant 5-hydroxytryptamine receptors coupled to distinct signaling pathways in intestinal muscle cells: convergence of the pathways on Ca2+ mobilization.
    Kuemmerle JF; Martin DC; Murthy KS; Kellum JM; Grider JR; Makhlouf GM
    Mol Pharmacol; 1992 Dec; 42(6):1090-6. PubMed ID: 1336114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells.
    Xu J; Jian B; Chu R; Lu Z; Li Q; Dunlop J; Rosenzweig-Lipson S; McGonigle P; Levy RJ; Liang B
    Am J Pathol; 2002 Dec; 161(6):2209-18. PubMed ID: 12466135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants.
    Kidd M; Modlin IM; Gustafsson BI; Drozdov I; Hauso O; Pfragner R
    Am J Physiol Gastrointest Liver Physiol; 2008 Aug; 295(2):G260-72. PubMed ID: 18556422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depletion of serotonin and selective inhibition of 2B receptor suppressed tumor angiogenesis by inhibiting endothelial nitric oxide synthase and extracellular signal-regulated kinase 1/2 phosphorylation.
    Asada M; Ebihara S; Yamanda S; Niu K; Okazaki T; Sora I; Arai H
    Neoplasia; 2009 Apr; 11(4):408-17. PubMed ID: 19308295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a 5-hydroxytryptamine (5-HT2) receptor on guinea pig small intestinal crypt cells.
    Siriwardena AK; Smith EH; Borum EH; Kellum JM
    Am J Physiol; 1993 Aug; 265(2 Pt 1):G339-46. PubMed ID: 8368315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells.
    von Hessert-Vaudoncourt C; Lelek S; Geisler C; Hartung T; Bröker V; Briest F; Mochmann L; Jost-Brinkmann F; Sedding D; Benecke J; Freitag H; Wolfshöfer S; Lammert H; Nölting S; Hummel M; Schrader J; Grabowski P
    Front Pharmacol; 2024; 15():1308686. PubMed ID: 38375032
    [No Abstract]   [Full Text] [Related]  

  • 20. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
    Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
    Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.